首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer.
【24h】

The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer.

机译:神经元特异性烯醇化酶(NSE)和Cyfra21-1在小细胞肺癌中的预后价值。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: The aim of this study was to verify the prognostic significance of multiple tumour markers in small cell lung cancer (SCLC). PATIENTS AND METHODS: We examined seven tumour markers [carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA 19-9), squamous cell carcinoma antigen (SCC), neuron-specific enolase (NSE), cancer antigen 125 (CA125), cytokeratin 19 fragment (Cyfra21-1) and ProGastrin-releasing peptide (ProGRP)] in 57 small cell lung cancer (SCLC) patients. RESULTS: Univariate analysis showed that NSE and Cyfra21-1 were independent negative prognostic factors along with gender, therapy and lactate dehydrogenase (LDH). Multivariate analysis showed that both NSE and Cyfra21-1 retained their significance as prognostic factors along with therapy and the respective hazard ratios were 3.918 (p=0.0122) and 2.617 (p=0.0318) among the seven tumour markers. The group with both NSE and Cyfra21-1 positive had a worse prognosis than the only NSE-positive group, with the respective hazard ratios being 10.245 (p=0.0004) and 3.913 (p=0.0123). CONCLUSION: The group with both of the markers NSE and Cyfra21-1 positive had a worse prognosis than the only NSE-positive group.
机译:目的:本研究的目的是验证多种肿瘤标志物在小细胞肺癌(SCLC)中的预后意义。病人和方法:我们检查了七个肿瘤标志物[癌胚抗原(CEA),癌抗原19-9(CA 19-9),鳞状细胞癌抗原(SCC),神经元特异性烯醇化酶(NSE),癌抗原125(CA125)。 ,细胞角蛋白19片段(Cyfra21-1)和ProGastrin释放肽(ProGRP)]在57例小细胞肺癌(SCLC)患者中。结果:单因素分析显示,NSE和Cyfra21-1与性别,治疗和乳酸脱氢酶(LDH)均为独立的阴性预后因素。多变量分析显示,NSE和Cyfra21-1均与治疗一起保留其作为预后因素的意义,在这7种肿瘤标志物中,各自的危险比分别为3.918(p = 0.0122)和2.617(p = 0.0318)。 NSE和Cyfra21-1阳性的组的预后均比唯一NSE阳性的组差,其危险比分别为10.245(p = 0.0004)和3.913(p = 0.0123)。结论:NSE和Cyfra21-1标志均为阳性的组预后较唯一NSE阳性组差。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号